WebbSmoking and adverse outcomes in patients with CKD: Am J Kidney Dis. 2016 Apr 22. pii: S0272-6386(16)00699-5; The use of causal diagrams: An example from SHARP. Clin J … Webb7 feb. 2024 · The Dapagliflozin And Prevention of Adverse outcomes in CKD (DAPA-CKD) trial is testing the hypothesis that treatment with dapagliflozin is superior to placebo in reducing the risk of renal and cardiovascular events in patients with CKD (with or without concomitant type 2 diabetes) already receiving an optimized dose of either an …
ASSESSING BASELINE MEDICATION USE IN CHRONIC KIDNEY …
Webb1 juni 2003 · Abstract. Study of Heart and Renal Protection (SHARP). Among patients with preexisting coronary heart disease, large-scale randomized trials have demonstrated … Webb11 apr. 2024 · 30) I hope you found this #accredited #tweetorial useful & have learned more about individualized strategies to risk-stratify, manage, & educate pts with advancing #CKD in the setting of #T2D! 国土交通省 gisとは
Lipidomic approaches to dissect dysregulated lipid metabolism ... - Nature
Webb1 dec. 2014 · Introduction. Published in 2011, the SHARP (Study of Heart and Renal Protection) trial 1 questioned if there is any cardiovascular benefit to LDL-lowering therapy in a chronic kidney disease (CKD) population (both nondialysis and dialysis). The benefit of statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) in secondary … Webb14 okt. 2024 · Conclusion: The SHARP-ER study will contribute important evidence on the long-term outcomes of cholesterol-lowering therapy in patients with advanced CKD with … Webb20 nov. 2010 · SHARP is the largest prospective study of LDL-lowering in patients with CKD SHARP is the largest clinical trial of VYTORIN conducted to date, and enrolled a total of 9,438 patients under the care of a nephrologist for chronic kidney disease. 国土交通省 dm フォーマット